The use of immunotherapy in the treatment of melanoma

Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully overcomes this tumor-mediated immune suppression has made the greatest impact in the management of this disease over the past few years. This progress through immunotherapy builds upon earlier successes that interferon-α had in the treatment of melanoma in the adjuvant setting, as well as that of high-dose interleukin-2 in advanced melanoma. The development of immune checkpoint inhibitors has led to dramatic clinical activity in advanced melanoma. In particular, anti-CTLA4 and anti-PD1 monoclonal antibodies have taken us forward into the realm of longer survival and durable responses with the possibility of cure in a continuously increasing proportion of patients. Combination immunotherapeutic strategies and novel immunotherapeutic agents are being tested at an accelerated pace where the outlook for long-term survival benefits for the majority of patients appears brighter than ever.

• Publication year

  2017

• Venue

  Journal of Hematology & Oncology

• Publication date

  2017-04-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13045-017-0458-3PMID 28434398PMCID 5402170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Journal of Hematology & Oncology

  2019cited by this paper
• Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

  2016cited by this paper
• melanoma and other skin tumoursIpilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

  2016cited by this paper
• Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

  2016cited by this paper
• Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

  2016cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.

  2015cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

  2014cited by this paper
• Abstract 2911: Immune related melanoma gene expression profile predicts neoadjuvant ipilimumab clinical benefit

  2014cited by this paper
• Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

  2014cited by this paper
• Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

  2014cited by this paper
• Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

  2014cited by this paper
• Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

  2014cited by this paper
• Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

  2013cited by this paper
• Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

  2012cited by this paper
• Immunotherapy of cancer in 2012

  2012cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012influential reference
• Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

  2012cited by this paper
• Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

  2012cited by this paper
• Tumor-Infiltrating Lymphocytes in Melanoma

  2012influential reference
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Endothelial Nitric Oxide Synthase Is a Key Mediator of Interleukin-2-Induced Hypotension and Vascular Leak Syndrome

  2011cited by this paper
• CA : A Cancer Journal for Clinicians

  2011cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

  2010cited by this paper
• Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  2010cited by this paper
• Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Biology and clinical applications of CD40 in cancer treatment.

  2010cited by this paper
• Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.

  2009cited by this paper
• What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?

  2009cited by this paper
• Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

  2008cited by this paper
• 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2b

  2007cited by this paper
• The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

  2007cited by this paper
• Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

  2007cited by this paper
• Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b

  2007cited by this paper
• Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

  2007cited by this paper
• Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist1

  2007cited by this paper
• IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

  2006cited by this paper
• Identifying and Overcoming Immune Resistance Mechanisms in the Melanoma Tumor Microenvironment

  2006cited by this paper
• Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

  2006cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

  2006cited by this paper
• Interleukin-2 for the treatment of melanoma.

  2005cited by this paper
• Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

  2005influential reference
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation

  2004cited by this paper
• Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1

  2004cited by this paper
• 4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

  2002cited by this paper
• Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

  2002cited by this paper
• New regulatory co-receptors: inducible co-stimulator and PD-1.

  2002cited by this paper
• CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity

  2002cited by this paper
• Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.

  2001cited by this paper
• PD-L2 is a second ligand for PD-1 and inhibits T cell activation

  2001cited by this paper
• Engagement of OX40 Enhances Antigen-Specific CD4+ T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of αOX-40 with αCTLA-41

  2001cited by this paper
• B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

  2001cited by this paper
• Inducible IL-2 production by dendritic cells revealed by global gene expression analysis

  2001cited by this paper
• Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.

  2001cited by this paper
• High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.

  2001cited by this paper
• High-dose interleukin-2 is an intensive treatment regardless of the venue of administration.

  2001cited by this paper
• High-dose interleukin-2 is an intensive treatment regardless of the venue of administration.

  2001cited by this paper
• Interferon‐alpha (IFN‐α) stimulates anti‐melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)

  2000cited by this paper
• High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

  2000influential reference
• Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

  2000cited by this paper
• Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

  1999cited by this paper
• Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

  1999cited by this paper
• B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

  1999cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

  1999cited by this paper
• Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis.

  1998cited by this paper
• Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells

  1998cited by this paper
• Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells

  1997cited by this paper
• Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement.

  1996cited by this paper
• Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development.

  1996cited by this paper

• Emerging roles of IL4I1 in regulating tumor immunity and ferroptosis.

  2026cites this paper
• Dual-Membrane-Camouflaged Engineered Bacteria for Targeted Melanoma Therapy.

  2025cites this paper
• Inhibition of PD-L1/PD-1 Checkpoint Increases NK Cell-Mediated Killing of Melanoma Cells in the Presence of Interferon-Beta

  2025cites this paper
• IMMUNOTHERAPY IN THE FIGHT AGAINST MELANOMA: CHALLENGES AND DEVELOPMENT PERSPECTIVES- A LITERATURE REVIEW

  2025cites this paper
• Oxygen-Generating Transdermal Nanoplatform Codelivering BRD4 Proteolysis-Targeting Chimera/Verteporfin/CaO2 Synergistically Remodels Immunosuppressive Melanoma Microenvironment to Potentiate Combination Immunotherapy.

  2025cites this paper
• DNA vaccines as promising immuno-therapeutics against cancer: a new insight

  2025cites this paper
• Precision-engineered bacterial nanovectors for synergetic co-delivery to harness cellular senescence and immunomodulation for enhanced tumor eradication

  2025cites this paper
• “Convex Lens” of DNA damage: A nanomedicine enhances anti-PD-1 immunotherapy as immunogenic cell death inducer for “cold” melanoma

  2025cites this paper
• Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

  2024cites this paper
• Alleviating hypoxia to improve cancer immunotherapy

  2023cites this paper
• Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment

  2023cites this paper
• Microneedle Patch Integrated with Porous Silicon Confined Dual Nanozymes for Synergistic and Hyperthermia‐Enhanced Nanocatalytic Ferroptosis Treatment of Melanoma

  2023cites this paper
• Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma.

  2023cites this paper
• Bulk and single-cell RNA-sequencing analyses along with abundant machine learning methods identify a novel monocyte signature in SKCM

  2023cites this paper
• Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment

  2023cites this paper
• SPARTIN: a Bayesian method for the quantification and characterization of cell type interactions in spatial pathology data

  2023cites this paper
• Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review

  2022cites this paper
• Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS)

  2022cites this paper
• Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives

  2022cites this paper
• Research status and prospect of immune checkpoint inhibitors for melanoma

  2022cites this paper
• Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises.

  2022cites this paper
• The integration of single-cell sequencing, TCGA, and GEO data analysis revealed that PRRT3-AS1 is a biomarker and therapeutic target of SKCM

  2022cites this paper
• Immunization with placenta-specific 1 (plac1) induces potent anti-tumor responses and prolongs survival in a mouse model of melanoma.

  2022cites this paper
• Recent advances in immunotherapy for the treatment of malignant melanoma.

  2022cites this paper
• Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4+ T cells in melanomas

  2022cites this paper
• Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content

  2022cites this paper
• Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS)

  2022cites this paper
• A snapshot of the PD-1/PD-L1 pathway

  2021cites this paper
• Boron neutron capture therapy in clinical application:Progress and prospect

  2021cites this paper
• Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients

  2021cites this paper
• Combined mRNAs and clinical factors model on predicting prognosis in patients with triple-negative breast cancer

  2021cites this paper
• Signal pathways of melanoma and targeted therapy

  2021cites this paper
• Impact of adjuvant therapies following surgery for anal melanoma.

  2021cites this paper
• Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?

  2021cites this paper
• Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.

  2021cites this paper
• Recombinant CD137‐Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus

  2021cites this paper
• Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response

  2021cites this paper
• Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells

  2021cites this paper
• Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer

  2021cites this paper
• Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells

  2021cites this paper
• Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials

  2021cites this paper
• Palliative care in the context of immune and targeted therapies: A qualitative study of bereaved carers’ experiences in metastatic melanoma

  2020cites this paper
• Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

  2020cites this paper
• Boron Chemistry for Medical Applications

  2020cites this paper
• Boron neutron capture therapy at the crossroads - Where do we go from here?

  2020cites this paper
• BRAF in malignant melanoma progression and metastasis: potentials and challenges.

  2020cites this paper
• Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review.

  2020cites this paper
• Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy

  2020cites this paper
• Rewiring Mitochondrial Metabolism for CD8+ T Cell Memory Formation and Effective Cancer Immunotherapy

  2020cites this paper
• Basis for Immunotherapy for Treatment of Meningiomas

  2020cites this paper
• Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort.

  2020cites this paper
• Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)

  2020cites this paper
• Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft

  2020cites this paper
• Exosomal melanotransferrin as a potential biomarker for metastatic melanoma

  2020cites this paper
• Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.

  2019cites this paper
• Suppression of connexin 43 expression by miR-106a promotes melanoma cell proliferation.

  2019cites this paper
• Recent advances in localized immunotherapy of skin cancers.

  2019cites this paper
• Effets secondaires rénaux chez les patients traités par immunothérapie par anti-PD1 pour mélanome métastatique : étude réalisée en vie réelle dans une cohorte de 239 patients

  2019cites this paper
• MiR-155 inhibits proliferation, invasion and migration of melanoma via targeting CBL.

  2019cites this paper
• Anti-PD-1immunotherapy in advanced metastatic melanoma: State of the art and future challenges.

  2019cites this paper
• Prognosis and Management of Thick and Ultrathick Melanoma

  2019cites this paper
• An outreach telephone program for advanced melanoma supportive care: Acceptability and feasibility.

  2019cites this paper
• Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies

  2019cites this paper
• Systemic Therapies for Advanced Melanoma.

  2019cites this paper
• Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.

  2019cites this paper
• Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy.

  2019cites this paper
• Molecular background of skin melanoma development and progression: therapeutic implications

  2019influential citation
• Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab

  2019cites this paper
• Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma.

  2019cites this paper
• Cancer DNA vaccines: current preclinical and clinical developments and future perspectives

  2019cites this paper
• Development and validation of an immune prognostic signature for ovarian carcinoma.

  2019cites this paper
• Destabilization of β‐Hemocyanin from Helix pomatia in Presence of Choline Amino Acids Results in Improved Cell Specificity and Cytotoxicity against Human Breast Cancer

  2019cites this paper
• To each his own: a personalized vaccine for metastatic melanoma.

  2019cites this paper
• Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol

  2018cites this paper
• Melanoma and Immune Checkpoint Inhibitors

  2018cites this paper
• The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer.

  2018cites this paper
• Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.

  2018cites this paper
• Kompletní léčebná odpověď po anti-PD1 terapii u pacientky s pokročilým melanomem a rezistencí na cílenou terapii BRAF inhibitory

  2018cites this paper
• Combatting mucosal melanoma: recent advances and future perspectives

  2018cites this paper
• E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma

  2018cites this paper
• Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

  2018cites this paper
• Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine.

  2018cites this paper
• Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.

  2018cites this paper
• Resection for anal melanoma: Is there an optimal approach?

  2018cites this paper
• Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

  2018cites this paper
• It is finally time for adjuvant therapy in melanoma.

  2018cites this paper
• A realistic appraisal of boron neutron capture therapy as a cancer treatment modality

  2018cites this paper
• Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses

  2018cites this paper
• A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity.

  2018cites this paper
• Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

  2018cites this paper
• Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma.

  2018cites this paper
• The natural history of thin melanoma and the utility of sentinel lymph node biopsy

  2017cites this paper
• Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient

  2017cites this paper
• Measuring Markers of Immune Response in Patients Treated with Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®)

  2017cites this paper
• Current progress in innovative engineered antibodies

  2017cites this paper
• Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer

  2017cites this paper
• Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

  2017cites this paper
• Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma

  2017cites this paper
• MiR-219-5p Inhibits the Growth and Metastasis of Malignant Melanoma by Targeting BCL-2

  2017cites this paper
• Targeting immune checkpoints in breast cancer: an update of early results

  2017cites this paper